Ocular distribution of lomefloxacin 0.3 % After a single instillation in the infected eye of pigmented rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 13, Issue 6, 1997, Pages 551-558

  Elena, Pierre Paul ^a   Jauch, Arthur ^b  

^a Iris Pharma   (France)

^b CIBA Vision   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LOMEFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; EYE INFECTION; GOOD LABORATORY PRACTICE; LACRIMAL FLUID; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RABBIT; TOPICAL DRUG ADMINISTRATION;

EID: 0031472890     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1997.13.551     Document Type: Article

References (25)

1. Richman, J., Zolezio, H., and Tang-Liu D. Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90 % of test organisms. Antimicrob. Agents Chemother. 34(8): 1602-1604, 1990.
2. Wadworth, A.N. and Goa, K.L. Lomefloxacin - A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs (Adis Int.) 42 (6): 1018-1060, 1991.
3. Yokota, T., Suzuki, E., and Arai, K. NY-198, a novel new quinolone, its in vitro antibacterial activity, cytotoxicity for mammalian cells, and synergy of bactericidal activity with mouse-cultured marcrophages. Chemotherapy 36 (S-2):25-35, 1988.
4. Pruul, H. and McDonald, P.J. Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils. J. Antimicrob. Chemother. 25:91-101, 1990.
5. Debbia, E., Pesce, A., and Schito, G.C. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens. The Am. J. Med. 92 suppl 4a:45S-47S, 1992.
6. 14NY-198 in rats and dogs. Chemotherapy 36 (S-2):151-173, 1988.
7. Yanagida, T., Yamada, T., Takahasi, K., Okezaki, E., Nakanishi, H., and Nagata, O. Disposition and metabolism of NY-198 : III. Absorption, metabolism and excretion of NY-198 in monkeys by high-performance liquid chromatography. Chemotherapy 36 (S-2):144-150, 1988.
8. Takahashi, Y., Okezaki, E., Ohmichi, K., Makino, E., and Koike, S. Bacteriological evaluation of NY-198. Chemotherapy 36 (S-2):99-111, 1988.
9. Hirase, T. and Inoue, M. In vitro and in vivo antibacterial activities of NY-198. Chemotherapy 36 (S-2):1-24, 1988.
10. Kanimoto, Y., Miwa, Y., Shimizu, Y., and Kawada, Y. Antimicrobial activity, pharmacokinetics in impaired renal function and clinical efficacy in urinary tract infections of NY-198. Chemotherapy 36/Suppl. 2 (II):896-908, 1988.
11. Nagatake, T., Matsumoto, K., Shishido, H., Rikitomi, N., Tao, M., Takasugi, M., Sakamoto, T., Takahashi, A., Oishi, K., Nshiara, and M., Watanabe, K. In vitro antibacterial activity, penetration into sputum, and clinical evaluation in chronic respiratory tract infections of NY-198, a new DNA gyrase inhibitor. Chemotherapy 36/Suppl. 2(II):763-773, 1988.
12. Ooishi, M., Oomomo, A., Sakaue, F., Tazawa, H., Miyao, M., Kuriyama, H., Ikerjiri, Y., and Samejima, S. Studies on intraocular penetration of NY-198 (lomefloxacin) eye drops. Acta Soc. Ophthalmol. Jpn. 92, 11:1825-1832, 1988.
13. Fukuda, M., Chou, J.S., and Sasaki, K. Intraocular dynamic of a new antibacterial derivative of pyridone carboxylic acid (NY-198). Folia Ophthalmol. Jpn 40/1:72-76, 1989.
14. Kodama, T. Penetration of lomefloxacin ophthalmic solution (NY-198) into the human aqueous humor. Jpn. Rev. Ophthalmol. 85:493-495, 1991.
15. Nos-Barbera, S., Portoles, M., Igual, A., Fernandez-Puigcarbo, E., and Diez-Noguera, A. A method to evaluate the activity of antimicrobial agents in a model of induced bacterial keratitis. Proc. 8th Intl. Soc.Eye Res. (ICER) April 9, 1988, San Francisco, USA.
16. Colin, J., Malet, F., Jauch, A., and Abalain M.L. Bacterial keratitis therapy in guinea pigs with lomefloxacin with initially high. followed by low dosage regimen. Ophthalmic Res. 27:322-329, 1995.
17. Uchida, Y. Evaluation of lomefloxacin (NY-198) ophthalmic solution. A multi-center phase two double-blind clinical trial. Jpn. Rev. Ophthalmol. 84:51-58, 1990.
18. Uchida, Y. Clinical efficacy of topical lomefloxacin (NY-198) in bacterial infections of the external eye. A multicenter double blind phase III study. Folia Ophthalmol. Jpn. 42:59-70, 1991.
19. Huguet, P. Clinical study with lomefloxacin 0.3 % eye drops (DR 1303) in comparison with ofloxacin 0.3% eye drops (Tarivid) in the treatment of acute bacterial conjunctivitis. Proc. IX Congr. Eur. Soc. Ophthalmol. (SOE 92) Brussels, May 23-28, 1992, abstract 644, 163.
20. Guex-Crosier, Y., Nussbaum, R., Herbort, C., Jauch, A., et al. Double masked double dummy clinical multicenter trial in Switzerland between lomefloxacin 0.3 % (DR 1303) eye drops and gentamicin 0.3 % eye drops in patients with acute bacterial conjunctivitis. Proc. Ann. Congr. Ophthalmic Soc. Switzerland (SOG) Sept. 15, 17, 1994, Aarau, Switzerland.
21. Malminiemi, K., Kari, O., Latvala M.L., Voutilainen R., Mietinen A., and Jauch, A. Topical lomefloxacin twice daily compared with fusidic acid in acute bacterial conjunctivitis. Acta Ophthalmol. Scand. 74:280-284, 1996.
22. Fukuda, M. and Sasaki, K. Intraocular dynamic mode differences of new quinolone antibacterial agents between pigmented and albino rabbit eyes. Lens Eye Toxic. Res. 6:339-351, 1989.
23. Fukuda, M., Tomii, T., Tsuzuki, H., and Sasaki, K. Measurement of cephaloridine and ofloxacin in cul de sac. J. Eye (Jpn) 2:1450-1453, 1985.
24. Donnerfeld, E.D., Schrier, A., Perry, H.D., Aulicino, T., Gombert, M.E., and Nelson, D.B. Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor. Ophthalomology 101:902-905, 1992.
25. Hatano, H., Inoue, K., Shia, S., and Wang, L. Application of topical lomefloxacin against experimental Pseudomonas endophthalmitis in rabbits. Acta Ophthalmologica 71:660-670, 1993.